^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Polivy (polatuzumab vedotin-piiq) (Microtubule inhibitor, CD79b-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Roche Press Release
    Title:

    FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma

    Published date:
    04/19/2023
    Excerpt:
    Roche...announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL)...
    Secondary therapy:
    R-CHP
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Chugai Press Release
    Title:

    Chugai Obtains Approval for Polivy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Published date:
    03/23/2021
    Excerpt:
    ...Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the anticancer agent/antimicrotubule binding anti-CD79b monoclonal antibody Polivy® intravenous infusion 30mg and 140mg [generic name: polatuzumab vedotin (genetical recombination)] in combination with bendamustine (freeze-dried formulation) and rituximab...
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    01/16/2020
    Excerpt:
    Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

    Published date:
    09/23/2020
    Excerpt:
    Polatuzumab vedotin with rituximab and bendamustine is recommended, within its marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B-cell Lymphoma: Preferred Regimen...Polatuzumab vedotin+/-Rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B Cell Lymphoma: Preferred regimens...Polatuzumab vedotin ± bendamustine ± rituximab
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Blood
    Title:

    Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

    Published date:
    04/20/2023
    Excerpt:
    At data cutoff (28 June 2021; median follow-up 24.2 months), PFS met the consistency definition with the global population, and was superior with Pola-R-CHP vs R-CHOP (hazard ratio, 0.64; 95% confidence interval [CI], 0.40-1.03). Two-year PFS was 74.2% (95% CI, 65.7-82.7) and 66.5% (95% CI, 57.3-75.6) with Pola-R-CHP and R-CHOP, respectively....These findings demonstrate consistent efficacy and safety of Pola-R-CHP vs R-CHOP in the Asia and global populations in POLARIX.
    Secondary therapy:
    CHP
    DOI:
    10.1182/blood.2022017734
    Trial ID:
    POLARIX